B Braun Company Profile

What is the competitive landscape for B BRAUN

B BRAUN has one hundred and twenty-two approved drugs.

There are three US patents protecting B BRAUN drugs.

There are fifty patent family members on B BRAUN drugs in twenty-nine countries and two hundred and sixty-seven supplementary protection certificates in seventeen countries.

Summary for B Braun

International Patents:	50
US Patents:	3
Tradenames:	230
Ingredients:	68
NDAs:	122

Drugs and US Patents for B Braun

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	DEXTROSE 2.5% IN PLASTIC CONTAINER	dextrose	INJECTABLE;INJECTION	018358-001	Approved Prior to Jan 1, 1982		DISCN	No	No
B Braun	MANNITOL 10% IN PLASTIC CONTAINER	mannitol	INJECTABLE;INJECTION	020006-002	Jul 26, 1993	AP	RX	No	No
B Braun	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	dextrose; potassium chloride; sodium chloride	INJECTABLE;INJECTION	019630-028	Feb 17, 1988	AP	RX	No	No
B Braun	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	dextrose; potassium chloride; sodium chloride	INJECTABLE;INJECTION	019630-007	Feb 17, 1988		RX	No	No
B Braun	DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER	calcium chloride; dextrose; potassium chloride; sodium chloride	INJECTABLE;INJECTION	020000-001	Apr 17, 1992		DISCN	No	No

Expired US Patents for B Braun

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
B Braun	HEPATAMINE 8%	amino acids	INJECTABLE;INJECTION	018676-001	Aug 3, 1982	3,950,529
B Braun	UCEPHAN	sodium benzoate; sodium phenylacetate	SOLUTION;ORAL	019530-001	Dec 23, 1987	4,284,647

International Patents for B Braun Drugs

Country	Patent Number	Estimated Expiration
Serbia	53077
South Africa	201504618
Poland	2900216
Portugal	2900216
Russian Federation	2648823

Supplementary Protection Certificates for B Braun Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0496835	C960031	Netherlands		PRODUCT NAME: DOXORUBICINESULFAAT VERKREGEN UIT DOXORUBICINEHYDROCHLORIDE EN AMMONIUMSULFAAT; REGISTRATION NO/DATE: EU/1/96/011/001 - EU/1/96/011/002 19960621
0925294	56/2007	Austria		PRODUCT NAME: 1-OXO-2(2,6-DIOXOPIPERIDIN-3-YL)-4- AMINOISOINDOLIN, AUCH 3-(4'AMINOISOINDOLIN-1'-ON)- 1-PIPERIDIN-2,6DION GENANNT, GEGEBENENFALLS IN FORM EINES SAEUREADDITIONSSALZES; REGISTRATION NO/DATE: EU/1/07/391/001 - EU/1/07/391/004 20070614
1856135	2090014-8	Sweden		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE OR SOLVATE OF FOSTAMATINIB OR THE PH ARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
1666481	C 2017 029	Romania		PRODUCT NAME: TOFACITINIB, OPTIONAL SUB FORMA UNEI SARI ACCEPTABILE FARMACEUTIC, INCLUSIV SAREA CITRAT 3-((3R,4R)-4-METIL-3-{METIL-(7H-PIROLO[2,3-D]PIRIMIDIN-4-IL)-AMINO]PERIDINIL)-3-OXO-PROPIONITRIL; NATIONAL AUTHORISATION NUMBER: EU/1/17/1178; DATE OF NATIONAL AUTHORISATION: 20170322; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1178; DATE OF FIRST AUTHORISATION IN EEA: 20170322
0693475	CR 2010 00036	Denmark		PRODUCT NAME: TAPENTADOL ((1R-2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL), HERUNDER HYDROCHLORIDET; NAT. REG. NO/DATE: 45151-45158, 45162-45169 20100830; FIRST REG. NO/DATE: EU 75043.00.00-75048.00.00, 75261.00.00-75270.00.00 20100819

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• B Braun
• B Braun Medical

Pharmaceutical Competitive Landscape Analysis: B. Braun – Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

What is B. Braun's Position in the Pharmaceutical Industry?

B. Braun operates primarily in healthcare products and services, with a focus on infusion therapies, critical care, and surgical instruments. It maintains a strong presence in hospital settings across North America, Europe, and Asia. Although not a conventional pharmaceutical company, it develops and supplies active pharmaceutical ingredients (APIs), particularly in anesthesia, pain management, and specialty therapies.

Market Share and Revenue (2022):

• Total revenue: €8.1 billion
• Pharmaceuticals segment accounts for approximately 12% (€972 million) of total revenue
• Operates in over 60 countries with a presence in hospital care, outpatient clinics, and home care

Competitive Position:
B. Braun ranks among the top 10 medical device companies globally. Its pharmaceutical activities are more niche, focusing on high-margin hospital pharmaceutical products rather than broad-based drug manufacturing. The company's diversified portfolio reduces dependency on any single product category.

How Does B. Braun Compare with Major Competitors?

Company	Revenue (2022)	Core Focus	Market Reach	Notable Strengths
B. Braun	€8.1 billion	Hospital supplies, infusion therapy, select APIs	Global, especially Europe and North America	Integrated manufacturing, extensive hospital networks
Fresenius Kabi	€7.3 billion	IV drugs, infusion therapy, biosimilars	Over 100 countries	Broad pharmaceutical portfolio, strong presence in APIs
BD (Becton Dickinson)	€19.9 billion	Medical devices, pharmaceuticals	Worldwide	Innovative drug delivery devices, sterile solutions
Baxter Healthcare	€14.2 billion	IV therapies, renal, and surgical products	Over 100 countries	Diversified healthcare solutions

B. Braun’s revenues and market share trail behind major pharmaceutical-focused firms like Fresenius Kabi and Baxter but compete effectively within hospital-centric segments.

What are B. Braun's Core Strengths?

Integrated Supply Chain

The company owns manufacturing facilities across continents, enabling control over quality and supply. This allows for rapid response to hospital needs and enhances reliability.

Focused Product Portfolio

B. Braun concentrates on infusion systems, surgical instruments, and specific hospital pharmaceuticals. Its expertise lies in high-margin products deployed in critical care, enabling sustained profitability.

Geographic Diversification

Presence in North America, Europe, and Asia provides regional stability and access to emerging markets. The company adapts its product offerings for local regulatory and clinical practices.

R&D Capabilities

Invests approximately €200 million annually in research and development. Key focus areas include needle safety, smart infusion systems, and novel pharmaceuticals for perioperative care.

Strategic Partnerships

Collaborations with biotech firms enable B. Braun to expand its pharmaceutical offerings. Notably, its partnership with BioNTech in vaccine delivery systems exemplifies such strategic moves.

What are the Strategic Opportunities for B. Braun?

Expansion in Biosimilars and Specialty Drugs

Growing demand for biosimilars and personalized therapies offers growth pathways in hospital and outpatient markets. B. Braun can leverage existing distribution channels to introduce generic biologics.

Digital and Smart Infusion Devices

Developing connected infusion systems can reduce medication errors and improve patient safety. B. Braun’s R&D investments support this transition.

Market Penetration in Emerging Economies

Expanding manufacturing and sales in Asia-Pacific and Latin America can capitalize on rising hospital infrastructure development and healthcare spending.

Strategic Acquisitions and Collaborations

Targeted acquisitions of innovative biotech firms can augment B. Braun’s portfolio of specialty pharmaceuticals and APIs.

Complying with Regulatory Changes

Proactive adaptation to evolving regulatory standards in the US (FDA), EU (EMA), and emerging markets ensures uninterrupted product access and competitive advantage.

What are the Challenges Facing B. Braun?

• Limited presence in broad-spectrum pharmaceuticals compared to top pharma firms.
• Regulatory complexity in diverse markets restricts rapid product launches.
• The hospital-centric business model faces pressures from outpatient and home care shifts.
• Competition from large pharma firms entering hospital supply segments with integrated pharmaceutical and device solutions.

Key Takeaways

• B. Braun maintains a prominent position within hospital-focused healthcare segments, demonstrating strengths in integrated manufacturing, geographic reach, and product specialization.
• It operates a niche pharmaceutical segment with growth potential in biosimilars, specialty therapies, and digital health.
• Strategic expansion into emerging markets and collaborations with biotech firms can mitigate growth limitations.
• Competition from diversified pharma companies and shifts toward outpatient care remain significant external pressures.

FAQs

1. What percentage of B. Braun’s revenue comes from pharmaceuticals?
Approximately 12% (€972 million of €8.1 billion total).

2. Which regions are B. Braun’s primary markets?
Europe, North America, and Asia.

3. Is B. Braun involved in biosimilar development?
Not extensively but explores biosimilars and specialty therapies through strategic collaborations.

4. How does B. Braun differentiate its product offerings?
Through integrated manufacturing, focus on hospital infusion and surgical products, and digital health solutions.

5. What growth opportunities exist for B. Braun in the next five years?
Expansion in biosimilars, digital infusion systems, and emerging markets; acquisitions of biotech firms; alignments with regulatory trends.

References

1. B. Braun Group. (2022). Annual Report 2022. Retrieved from https://www.bbraun.com
2. MarketsandMarkets. (2023). Infusion Therapy Devices Market.
3. Statista. (2023). Top Medical Device Companies Worldwide [Data set].
4. Forth, K. (2022). Strategic Review of Hospital Pharmaceutical Industry. Journal of Healthcare Business.